VJHemOnc Podcast iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
Nov 16, 2022
Experts Richard Stone and David Sallman discuss novel targets, combinations, and treatment strategies in AML. They explore the potential of drugs Eptenoprop and Magrolumab for TP53-mutated AML, and the importance of mature data sets and specific population focus in phase three trials. The use of complete remission rate as a primary endpoint for TP53 mutant patients is questioned, and CD47 inhibition as a potential therapy is explored.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 4min
Challenges and Speculations on the Results of a Phase Three Trial
04:07 • 3min
Exploring Primary Endpoints for TP53 Mutant Patients in AML
07:00 • 2min
CD47 inhibition and combination therapy for cancer cells
08:47 • 2min
Exploring the Potential of Anti-CD47 for Targeting P53 Mutant Cells in AML
10:44 • 2min